1 Reason Every Investor Should Know About Pfizer (PFE) Stock

Core Insights - Pfizer offers a high dividend yield of approximately 7%, significantly higher than the S&P 500's average yield of around 1.2% [1][3] - The company has a long history of dividend payments, having paid dividends for 347 consecutive quarters and increased payouts for 15 consecutive years [3] Financial Performance - Pfizer's recent forward-looking price-to-earnings (P/E) ratio is 8, below its five-year average of 10, indicating potential undervaluation [4] - In the second quarter, Pfizer reported a 10% year-over-year revenue increase and a 30% jump in earnings per share [4] - The company raised its full-year 2025 adjusted diluted EPS guidance, reflecting confidence in its strategic execution and shareholder returns [4] Growth Potential - Pfizer has a robust pipeline with over 50 programs and 80+ clinical trials globally, dedicating 40% of its R&D budget to oncology [4]